A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery Lesions (CREDIT)

A PILOT First-In-Man Study to Evaluate Safety and Efficacy of the EXCEL-Ⅱ With Cobalt Chromium Alloys Sirolimus Eluting Biodegradable Polymer Stent in the Treatment of Patients With de Novo Coronary Artery Lesions(CREDIT-I)

One of the purpose of this study is to assess the preliminary safety and feasibility,and to provide related information and evidence for the design of the further pivotal randomized control trial.the other purpose is to assess the performace of the stent delivery system.

Study Overview

• Status: Completed
• Conditions: Ischemia; Coronary Artery Disease
• Intervention / Treatment: Device: EXCEL-Ⅱ

Detailed Description

1. Single-center, prospective, pilot study
2. De novo,coronary artery, single vessel and single lesion
3. Sample size = 45
4. Follow- up clinical or phone at 1-month,9-month and annually 2 to 5 years
5. Randomization 2:1 Angio and OCT scheduled follow-up in the hospital
6. Follow-up Angio and OCT randomized 30 patients for 4-month and 15 patiens for 12-month

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Liaoning
    • Shenyang, Liaoning, China, 110015
      • Shenyang Northern Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. 18yrs≤Age≤75yrs .
2. De novo lesion at native coronary artery.
3. Single target vessel and single target lesion.
4. Lesion length ≤32mm.
5. RVD 2.5mm～4.0mm.
6. DS%≥70% by visual estimation.
7. Target lesion could be covered by only one stent.
8. Subjects are willing to follow the specified requirements follow-up.
9. A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate. Informed consent is documented by means of a written, signed and dated informed consent form.

Exclusion Criteria:

1. AMI within one week.
2. CTO(TIMI0),LM lesion,ostial lesion,graft vessel lesion,bifurcation (side branch RVD≥2.5mm),ISR,mutivessel disease need to be treated.
3. Severe calcified lesion unable to predilate.
4. extremely tortuous proximal to the lesion that is inadequate to stent delivery.
5. NYHA≥Ⅲ or LVEF≤40%.
6. Prior stenting within 1 year.
7. Pregnancy or lactation, and plan in postoperative pregnancy or lactation.
8. Subjects had bleeding tendency or blood coagulation dysfunction or PCI contraindications, or anticoagulant therapy taboo or can't continue DAPT healers at least 1 year.
9. There are other diseases (such as cancer,malignant tumor ,congestive heart failure,organ transplantation or candidate) or abuse history (alcohol cocaine heroin, etc.), scheme compliance is poor, interference related data explanation or the limited life (< 1 year).
10. To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast agent of one of allergy.
11. Serious liver and kidney function is not complete person.
12. The investigators think that do not fit to enroll the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: EXCEL-Ⅱ; A new Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions.	Device: EXCEL-Ⅱ; A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions; Other Names: CREDIT-Ⅰ

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary endpoint(MACE)	Device oriented cardiovascular endpoint at 30-day (MACE) defined as the composite of Cardiac Death,Myocardial Infarction(Q and non-Q) or Ischemia-driven Target Lesion Revascularization	30days(MACE)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary endpoint	In-stent Late Lumen Loss at 4-month and 12-month	5 years (Follow-up)

Collaborators and Investigators

• Sponsor: JW Medical Systems Ltd
• Investigators: Principal Investigator: Han y ling, PhD, Shenyang Northern Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2013
• Primary Completion (Actual): September 1, 2013
• Study Completion (Actual): June 4, 2019

Study Registration Dates

• First Submitted: February 5, 2013
• First Submitted That Met QC Criteria: July 24, 2013
• First Posted (Estimate): July 29, 2013

Study Record Updates

• Last Update Posted (Actual): April 26, 2023
• Last Update Submitted That Met QC Criteria: April 25, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: Death; MI; TLF; MACE; TVR
• Additional Relevant MeSH Terms: Pathologic Processes; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Disease; Coronary Artery Disease; Ischemia
• Other Study ID Numbers: H-2012-12